Literature DB >> 23507142

miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma.

Lei Chen1, Qing Wang, Guo-dong Wang, Hua-song Wang, Yong Huang, Xi-ming Liu, Xian-hua Cai.   

Abstract

Several miRNAs have been implicated in the development and progression of osteosarcoma (OS). In this study, we found that miR-16 is downregulated in OS cell lines and tissues. Overexpression of miR-16 suppresses OS cell proliferation and tumor growth in nude mice. Furthermore, we confirmed that IGF1R is a direct target of miR-16. Mechanistic investigation revealed that miR-16 overexpression inhibits the Raf1-MEK1/2-ERK1/2 pathway. In clinical specimens, IGF1R levels inversely correlate with miR-16 expression. Our results provide significant clues regarding the role of miR-16 as a tumor suppressor by targeting IGF1R in OS.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23507142     DOI: 10.1016/j.febslet.2013.03.007

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  47 in total

1.  MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-Hong Liu; Yurong Ouyang; Hong-Bin Guo; Hanchong Zhang; Jie Bu; Tao Xiao
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

2.  Association of MMP-2 expression and prognosis in osteosarcoma patients.

Authors:  Miao Zhang; Xuran Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 3.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 4.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

Review 5.  The validity of circulating microRNAs in oncology: five years of challenges and contradictions.

Authors:  J Jarry; D Schadendorf; C Greenwood; A Spatz; L C van Kempen
Journal:  Mol Oncol       Date:  2014-03-06       Impact factor: 6.603

6.  MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

Authors:  L Venturutti; R I Cordo Russo; M A Rivas; M F Mercogliano; F Izzo; R H Oakley; M G Pereyra; M De Martino; C J Proietti; P Yankilevich; J C Roa; P Guzmán; E Cortese; D H Allemand; T H Huang; E H Charreau; J A Cidlowski; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

7.  Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcoma.

Authors:  Nai-Guo Wang; Da-Chuan Wang; Bing-Yi Tan; Feng Wang; Ze-Nong Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 8.  Epigenetics of Skeletal Diseases.

Authors:  Alvaro Del Real; Leyre Riancho-Zarrabeitia; Laura López-Delgado; José A Riancho
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

Review 9.  Long non-coding RNAs: emerging players in osteosarcoma.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Tumour Biol       Date:  2015-12-30

10.  A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.

Authors:  Branden S Moriarity; George M Otto; Eric P Rahrmann; Susan K Rathe; Natalie K Wolf; Madison T Weg; Luke A Manlove; Rebecca S LaRue; Nuri A Temiz; Sam D Molyneux; Kwangmin Choi; Kevin J Holly; Aaron L Sarver; Milcah C Scott; Colleen L Forster; Jaime F Modiano; Chand Khanna; Stephen M Hewitt; Rama Khokha; Yi Yang; Richard Gorlick; Michael A Dyer; David A Largaespada
Journal:  Nat Genet       Date:  2015-05-11       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.